Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option
Related Posts
O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin[...]
Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi[...]
Karunanandaa K, Knoche EM, Montgomery RB, Pickett C, Doherty J, Gruber J, Raychaudhuri R, Eaton D, Garraway IP, Rettig M, Maxwell KN, Schoen MW. Tumor[...]